talmanco (previously tadalafil generics)
viatris limited - tadalafil - háþrýstingur, lungnabólga - Þvaglát - talmanco er ætlað í fullorðnir fyrir meðferð lungum slagæð háan blóðþrýsting (pah) flokkast sem hagnýtur ii og iii, til að bæta æfing getu. verkun hefur verið sýnd í sjálfvakta pah (ipah) og í pah í tengslum við krabbameinsvaldandi sjúkdóma.
metronidazol normon innrennslislyf, lausn 5 mg/ml
laboratorios normon, s.a. - metronidazolum inn - innrennslislyf, lausn - 5 mg/ml
altargo
glaxo group ltd - retapamulin - impetigo; staphylococcal skin infections - sýklalyf og krabbameinslyf til dýrafræðilegrar notkunar - short term treatment of the following superficial skin infections: , impetigo;, infected small lacerations, abrasions or sutured wounds. , sjáðu kafla 4. 4 og 5. 1 fyrir mikilvægar upplýsingar varðandi klínískum virkni retapamulin gegn mismunandi tegundir af Þegar sýkt merkið bit. Íhuga ætti að opinbera leiðsögn á réttri notkun af sýklalyfjum.
nystatin orifarm mixtúra, dreifa 100.000 a.e./ml
orifarm generics a/s - nystatinum inn - mixtúra, dreifa - 100.000 a.e./ml
ampicillin stada stungulyfs-/innrennslisstofn, lausn 1 g
stada nordic aps. - ampicillinum natríum - stungulyfs-/innrennslisstofn, lausn - 1 g
ampicillin stada stungulyfs-/innrennslisstofn, lausn 2 g
stada nordic aps. - ampicillinum natríum - stungulyfs-/innrennslisstofn, lausn - 2 g
flebogamma dif (previously flebogammadif)
instituto grifols s.a. - mönnum eðlilegt að notkun - mucocutaneous lymph node syndrome; guillain-barre syndrome; bone marrow transplantation; purpura, thrombocytopenic, idiopathic; immunologic deficiency syndromes - Ónæmiskerfið sera og mótefni, - replacement therapy in adults, children and adolescents (0-18 years) in: , primary immunodeficiency syndromes with impaired antibody production;, hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic luekaemia, in whom prophylactic antibiotics have failed;, hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who failed to respond to pneumococcal immunisation;, hypogammaglobulinaemia in patients after allogenic haematopoietic-stem-cell transplantation (hsct);, congenital aids with recurrent bacterial infections. , immunomodulation in adults, children and adolescents (0-18 years) in: , primary immune thrombocytopenia (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count;, guillain barré syndrome;, kawasaki disease.
tygacil
pfizer europe ma eeig - tigecycline - bacterial infections; skin diseases, bacterial; soft tissue infections - sýklalyf fyrir almenn nota, - tygacil is indicated in adults and in children from the age of eight years for the treatment of the following infections: , complicated skin and soft tissue infections (cssti), excluding diabetic foot infections, complicated intra-abdominal infections (ciai) , tygacil should be used only in situations where other alternative antibiotics are not suitable. Íhuga ætti að opinbera leiðsögn á réttri notkun af sýklalyfjum. viðeigandi að nota af sýklalyfjum.
fucidin smyrsli 20 mg/g
leo pharma a/s* - natrii fusidas nfn - smyrsli - 20 mg/g
fucidin krem 20 mg/g
leo pharma a/s* - acidum fusidicum inn - krem - 20 mg/g